O le ACOU085 na tu'uina atu i le tagata ma'i muamua e fa'aletonu le fa'alogo (presbycusis) i le Vaega 1b su'esu'ega fa'afoma'i i Siamani. O le suʻesuʻeina muamua o maʻi e fetaui ma le faʻavasegaina i totonu / tuusaunoaga mo le faʻataʻitaʻiga faʻaauau e toetoe lava a maeʻa. I le faaopoopo atu i le autu autu o le suʻesuʻega, suʻesuʻeina le saogalemu ma le gafatia o le vailaʻau faʻatau i tagata mo le taimi muamua, o loʻo faʻatautaia le tele o suʻega faʻalogo faʻapitoa ma faʻamoemoe e lagolago ai le suʻesuʻega o le faʻatatauga.

ACOU085 ose tama'i mole mole, otoprotective vaila'au sui o lo'o fa'avasegaina se mole mole fa'amanino lelei e fa'aalia i totonu o sela fa'alogo o le taliga i totonu, le mea e ta'ua o sela o fafo (OHC). O le ACOU085 o loʻo faʻaalia i se faiga faʻapitoa e lua: o le mole e faʻaosoina le faʻaleleia atili o le faʻalogo ma ofoina atu mo se taimi umi le faʻasaoina o OHC faʻamaʻi. Ia Tesema 2021, na tu'uina atu ai i le Acousia Therapeutics se CTA e le Siamani BfArM e amatalia ai lana fa'ata'ita'iga muamua-i-tagata Vaega 1b a le ACOU085.

“O le isi laasaga lenei a le sui tauva o fualaau oona a Acousia o ACOU085 i suʻesuʻega i tagata mamaʻi o loʻo mafatia i le presbycusis e faʻailogaina se tulaga taua tele i lo tatou ala i le faia o le faʻalogo o se faʻamaʻi e mafai ona togafitia," o le tala lea a Dr. Tim Boelke, Ofisa Sili o Pulega ma Ofisa Sili Fomai o le kamupani.

"Ou te matua mitamita lava ona o la matou galuega faʻasaienisi e faʻatatau i le mafaufau o loʻo agai nei i totonu o le falemaʻi i le na o le 6 tausaga talu ona amataina se polokalame o le atinaʻeina o vailaʻau faʻaonaponei i se tala fou, sili ona fou o fualaau faasaina," o le faaopoopo lea a Hubert Löwenheim, Polofesa ma Taitaifono o le Matagaluega o Otolaryngology-Ta'otoga Ulu & Ua o le Iunivesite o Tübingen ma le Acousia Therapeutics na faavaeina faatasi.

OA MEA E AVEA MAI LENEI TUSI:

In addition to the principle objective of the study, testing the safety and tolerability of the drug candidate in humans for the first time, a wide array of subjective and objective hearing tests are being conducted to support the investigation of target engagement.
ACOU085 is a proprietary small-molecule, otoprotective drug candidate that modulates a well-defined molecular target preferentially expressed in the sensory cells of the inner ear, the so-called outer hair cells (OHC).
“I am extremely proud that our hypothesis-driven, scientific work is now moving into the clinical stage only 6 years after initiating a full-fledged de novo drug development program on a novel, highly innovative drug target,”.